EPO and chronic kidney disease: Attempts to directly address CKD-associated anemia through treatment with recombinant EPO have generated mixed results [37,38], leading to efforts to develop gene and cell therapy based approaches for the targeted delivery of EPO in a physiologically relevant manner [35,39,40].